Neuromod Devices Ltd., a Dublin, Ireland-based medical device company specialising in tinnitus, closed a €10m equity financing in an expansion of its Series B round.
The round was led by existing investors Fountain Healthcare Partners and Panakès Partners.
The coompany intends to use the funds to accelerate commercialisation for Lenire in the USA and Europe.
Founded in 2010 by Dr. Ross O’Neill PhD, CEO, Neuromod Devices is a medical technology company which specialises in the design, development, and commercialisation of neuromodulation technologies to address the clinical needs of underserved patient populations who live with chronic and debilitating conditions. The lead application of Neuromod’s technology is tinnitus treatment device Lenire.
Neuromod has been making Lenire available through audiology and ENT practices throughout the USA and Europe. Following FDA approval in March 2023, more than 100 clinics throughout the USA now treat tinnitus patients with Lenire. Availability of Lenire has also expanded in Europe with clinics in 14 countries now using the device. In the last 6 months, the number of clinics in the UK trained to use Lenire has doubled.
FinSMEs
11/03/2025